You should be more excited this time around because CD12 made success in Brazil far more likely. There was a very small chance CD12 would fail for a couple of reasons and they both materialized — dosage not high enough and poorly distributed patients.

Like Recknor said to me personally: “ Not making those mistakes in Brazil.”